Efficacy of Azithromycin in MSAF Cases to Improve Maternal and Neonatal Outcomes

PHASE4CompletedINTERVENTIONAL
Enrollment

324

Participants

Timeline

Start Date

February 16, 2021

Primary Completion Date

May 31, 2021

Study Completion Date

October 4, 2021

Conditions
Meconium StainedAzithromycinPostpartum Endometritis
Interventions
DRUG

Azithromycin capsule (Zithromax, Pfizer) (250 mg)

Azithromycin, a second generation macrolide, broad-spectrum antibacterial that stops bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose. .Azithromycin has been beneficial in the treatment of influenza and Middle East respiratory syndrome coronavirus (MERS-CoV) and recently has shown to be effective against severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) when used in combination with hydroxychloroquine or chloroquine.

DRUG

Placebo

A treatment that has no active properties

Trial Locations (2)

002

Cairo University, Cairo

Cairo University, Giza

All Listed Sponsors
lead

Cairo University

OTHER

NCT05118984 - Efficacy of Azithromycin in MSAF Cases to Improve Maternal and Neonatal Outcomes | Biotech Hunter | Biotech Hunter